Skip to main content

Table 2 Incidence of clinical events in EINSTEIN DVT [25] and EINSTEIN PE [26]

From: Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist

Probability, mean (SE)

EINSTEIN DVT

EINSTEIN PE

Recurrent VTE (LMWH/VKA)

3-month population

0–3 months

0.015 (0.008)

0.016 (0.011)

6-month population

0–3 months

0.024 (0.005)

0.016 (0.003)

3–6 months

0.003 (0.002)

0.002 (0.001)

12-month population

0–3 months

0.035 (0.009)

0.015 (0.004)

3–6 months

0.008 (0.004)

0.003 (0.002)

6–12 months

0.003 (0.003)

0.001 (0.001)

Lifelong population [61]

>12 months

0.700 (0.107)

0.700 (0.107)

Major bleeding (LMWH/VKA)

3-month population

0–3 months

0.020 (0.010)

0.041 (0.018)

6-month population

0–3 months

0.009 (0.003)

0.010 (0.003)

3–6 months

0.004 (0.002)

0.008 (0.003)

12-month population

0–3 months

0.002 (0.002)

0.013 (0.004)

3–6 months

– (0.002)

0.004 (0.002)

6–12 months

– (0.002)

0.006 (0.003)

Lifelong population [61]

>12 months

1.600 (0.245)

1.600 (0.245)

NMCR bleeding (LMWH/VKA)

3-month population

0–3 months

0.060 (0.017)

0.066 (0.022)

6-month population

0–3 months

0.047 (0.006)

0.067 (0.007)

3–6 months

0.013 (0.004)

0.022 (0.004)

12-month population

0–3 months

0.049 (0.01)

0.062 (0.008)

3–6 months

0.024 (0.008)

0.029 (0.006)

6–12 months

0.038 (0.01)

0.030 (0.006)

Lifelong population

>12 months

0.014 (0.002)

0.022 (0.002)

  1. LMWH, low molecular weight heparin; NMCR, non-major clinically relevant; SE standard error; VKA, vitamin K antagonist; VTE, venous thromboembolism.